Drug Database
Back to search

Belgium· BE-AMP-SAM662024-00

Ebglyss 250 mg

A interleukin inhibitors product containing lebrikizumab, registered in Belgium by Almirall. The same ATC class is registered in 3 of our 19 countries.

ATC L04AC

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedEbglyss 250 mgATCL04ACREGISTER NO.BE-AMP-SAM662024-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lebrikizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lebrikizumab is registered in 3 of 19 countries.

Countries holding a registration under ATC L04AC (interleukin inhibitors), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 2 of them publish a price we can compare per daily dose
Search lebrikizumab products by name

Lebrikizumab · ATC L04AC

3 / 19 countries

  • Belgiumprice
  • Ireland
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lebrikizumab
Manufacturer
Almirall
Country
Belgium (BE)
ATC code
L04AC
ATC class
Interleukin inhibitors
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

2 priced
  • be_apb
    4785697
    EUR 2011
  • be_apb
    4785481
    EUR 3011.01
  • be_apb
    7742323

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lebrikizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lebrikizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ebglyss
  • Liechtenstein · Ebglyss
  • Norway · Ebglyss

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5e5f6eb7-21ca-4c7d-a2f4-0da2f857a24d
GET /v1/drugs/5e5f6eb7-21ca-4c7d-a2f4-0da2f857a24d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ebglyss 250 mg",
  "name_fr": "Ebglyss 250 mg",
  "name_nl": "Ebglyss 250 mg",
  "amp_code": "SAM662024-00",
  "strengths": [
    "250.0000",
    "250.0000"
  ],
  "pack_count": 6,
  "substances": [
    "Lebrikizumab",
    "Sucrose",
    "Polysorbate 20"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Interleukin Inhibitors",
  "authorisation_numbers": [
    "EU/1/23/1765/001",
    "EU/1/23/1765/006",
    "EU/1/23/1765/004",
    "EU/1/23/1765/005",
    "EU/1/23/1765/002",
    "EU/1/23/1765/003"
  ]
}
API referenceMCP serverPlans

See everything about lebrikizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console